SLC5A2 and hydrops fetalis: Exclusion of the SOLOIST-WHF (10) trial, the Carballo (2020) study (20), and the trial by Nakagaito et al. (11) resulted in a statistically significant difference in readmissions due to HF in the SGLT2 inhibitors group compared to the control group (RR = 0.62, 95% CI: 0.47–0.80, P < 0.05, I2 = 0%) (Figure 6C).